MEDIPOST is the company that proved its end-to-end capability—from cell therapy development to manufacturing, quality control, and supply—through the commercialization of CARTISTEM®, Korea’s first allogeneic umbilical cord blood-derived stem cell therapy.
Building on NGF37, our human umbilical cord blood cell culture medium, we have also expanded into the commercial cosmetic ingredient space, accumulating cell-based commercialization experience spanning both therapeutics and cosmetic ingredients.
This experience extends beyond simple manufacturing services into an execution-driven CDMO service that helps translate our clients’ pipelines into real commercialization.
Allogeneic Umbilical Cord Blood-Derived Mesenchymal Stem Cells
Cell Therapy Contract Development & Manufacturing
Human Cell/Tissue Conditioned Medium
Contract Storage
Microbial Validation / Cell Characterization Analysis
Biological Raw Material Donation Support
CDMO Service Offerings
Allogeneic Umbilical Cord Blood-Derived Mesenchymal Stem Cells
Based on a proven, commercialization-validated allogeneic umbilical cord blood-derived mesenchymal stem cell platform, MEDIPOST stably supplies cells optimized to clients’ development stage — from research-use (RUO) to GMP grade. Beyond simple cell supply, we also provide material transfer and quality standards designed with process development and commercialization in mind.
Cell Therapy Contract Development & Manufacturing
MEDIPOST manages projects in an integrated manner through a dedicated CDMO organization, from initial project planning through commercialization. Specialized personnel are involved at every stage — process development, technology transfer, GMP manufacturing, and quality control — to build a consistent-quality, reproducible manufacturing system. We also provide flexible manufacturing strategies and execution plans tailored to each client’s development stage and objectives.
Human Cell/Tissue Conditioned Medium (Cosmetic Ingredients)
Drawing on our manufacturing and supply experience with NGF37, our human umbilical cord blood cell culture medium, MEDIPOST provides contract development and manufacturing services for human cell/tissue culture media optimized to clients’ product concepts and development goals. Through a standardized manufacturing system operated under consistent standards — from raw material production to quality control and stable supply — we reliably deliver high-quality cosmetic ingredients.
Contract Storage
MEDIPOST provides specialized contract storage services optimized to the characteristics and storage conditions of various biological products, including raw materials, cell banks, drug substances, and finished pharmaceutical products. Through a systematic management system covering temperature and environmental control, inbound/outbound tracking, and quality maintenance, we continuously preserve product stability and quality
Microbial Validation / Cell Characterization Analysis
MEDIPOST provides microbial validation and cell characterization analysis services that comply with GMP-related regulations. From test design through result analysis, we operate systematically to ensure product safety and quality, maintaining consistent quality standards from development through commercialization.
Test items include:
1. Mycoplasma Testing
2. Sterility Testing
3. Rapid Microbial Detection Testing
4. Endotoxin Testing
5. Identity/Purity Testing (Cell Phenotype Analysis)
6. Differentiation Potential Testing (Osteogenic Differentiation)
Biological Raw Material Donation Support
Leveraging our network of partner hospitals, MEDIPOST provides donation linkage and sourcing support services for a range of biological raw materials, including peripheral blood, umbilical cord blood, umbilical cord tissue, and adipose tissue. We maintain a stable and sustainable raw material sourcing system in compliance with ethical standards and relevant regulations, supplying biological raw materials suited to research and development purposes.